Based on this theory, a number of anti-cytokine and antiinflammatory therapies are being tested in COVID-19, including anti–IL-6(R) antibodies, IL-1 receptor antagonists, and JAK/STAT inhibitors, with early trial results failing to demonstrate significant efficacy (2, 3, 9, 15–18). The gene discussed is SOAT1; the disease is COVID-19.